Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights
- Global Market Gene Therapy Landscape USD 24 Billion Opportunity
- Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies
- Gene Therapy Products Dosage & Price Analysis
- Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials
- Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company
- Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target
- Global & Regional Market Insight
For Cell Gene Therapy Report Sample Contact neeraj@kuickresearch.com
The increasing knowledge about the biology of diseases has shown that several genetic mutations are involved in the progression of disease including cancer, autoimmune disorders, and others. Gene therapy is a powerful technology which allows for modification of person’s genes in order to develop antibodies for treating or curating diseases. The gene therapy involves repairing of defective gene in vivo or delivering the gene product to target cells by clinical safe vehicle. The introduction of gene therapy has shown potential to offer patients with eligible rare genetic diseases a transformational clinical benefit and improve quality of life.
Previously, the field of gene therapy was struggling with numerous challenges and barriers such as immune responses and non-target effects. However, the recent approvals of gene therapy products underline the progress made by the field and growing importance in future therapies. Currently, more than 20 gene-therapy drugs/products have been approved in the clinic which is indicated for wide range of cancer, blood disorders, and autoimmune diseases. Apart from this, several other gene therapy products have been granted orphan designation which is indicated for the management of rare diseases. For instance, US FDA has recently granted orphan drug designation to RGX-202, one-time experimental gene therapy for the management of Duchenne muscular dystrophy.
The encouraging response of gene therapies in the market have motivates other pharmaceutical companies to make investments in this sector. The key pharmaceutical companies are now focused on research and development sector pertaining to gene therapies. At present, researchers are utilizing gene therapies for various diseases including cancer, cystic fibrosis, hemophilia, AIDS, and diabetes. The companies are actively competing to gain approval and to enhance their market presence. In addition, several companies have also adopted several strategic alliances including collaboration, partnerships, or joint ventures. For instance, Scout Bio have recently expanded their foundational agreement with Gene therapy program (GTP) at University of Pennsylvania (Penn) to grant Scout Bio exclusive rights in the field of animal health to an emerging viral vector capsid technology for use in animal gene therapy, as well as extended option terms to other next-generation AAV vector technologies.
As per our report findings, the pipeline for novel gene therapy products is highly concentrated and is expected to flourish the market during forthcoming years. Currently, there are more than 2000 cell and gene therapy clinical trials ongoing globally which are evaluating the role of about 500 gene and cell therapy products and have shown promising response. For instance, in November 2021, Sio Gene Therapies reported positive interim data for gene therapy trial of Phase I/II of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis, a genetic disorder that progressively destroys nerve cells in the brain and spinal cord. The strong pipeline associated with the robust research and development activities suggests a positive future of gene therapy in pharmaceuticals market.
The global gene therapy market is anticipated to grow with high growth rates during the forecast period to surpass US$ 25 Billion by 2028. With the growing incidence of cancer and other targeted diseases such as genetic disorders, the adoption of gene therapy has significantly increased. Further, the growing product launches in the market and their enhanced efficacy over other treatments are also propelling the growth of market. Amid region, US is expected to witness significant growth in gene therapy market which is due to clinical trials combined with presence of key companies in the region. The major companies working in gene therapy market are Merck, Roche, Takeda Pharmaceutical, Novartis, Boehringer Ingelheim, Eli Lilly, and others which actively indulge in research and development activities. In addition, rising government initiatives and development of favorable reimbursement policies also propel the growth of regional market.
Contact:
Neeraj Chawla
Research Head
+919810410366
